

LAHIVE

&
COCKFIELD

LLP

MAR 06 2002

COUNSELORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lca@ahive.com

JOHN A. LAHIVE, JR., 1928-1991
THOMAS V. SMURZYNK
RALPH A. LIREN
GIULIA A. OHCOUNT, JR.
ANN LAMPORT-HAMM TEE
ELIZABETH A. HANLEY
AMY BAKER MANDRAZ, J.D.
ANTHONY A. LACHENTAN
KEVIN J. ANNUNZIATO
ANNE E. REMMELARD
DANIEL KURAN SMITH
PETER C. LAURIA
JEANNE M. GEORGE
DEBRA L. M. ALVAREZ, ESQ.
DAVID R. KEPERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, PH.D.
MEGAN E. WILLIAMS, PH.D.
RICHARD NAND
MICHAEL PHILIPPI, J.D.
LESA M. DRODICK
KATHARINE P. RUSSELL, J.D.
MARIA LAU, STRIKEZAI HAHAKU, PH.D.
CATHERINE DIMATTIA
CHRISTINE L. KELLY
MERRYLYNN ARNOLD, J.D.
SENIOR COUNSEL
ANNE E. REMMELARD
OF COUNSEL
JEREMY LYNCH
WILLIAM A. SOEFERD, J.D.
SIBYL P. REPPERT

PATENT AGENTS
THEODORE R. AEST
SHAYNEY HUFF, PH.D.
DANIEL B. KELLY

TECHNICAL SPECIALISTS
CYNTHIA M. SKIROS
PETER A. DUNI, PH.D.
E. PHILIPPE LEE
JENNIFER K. ROSEN, PH.D.
ALISON TAME SHAW, J.D.
CATHERINE E. MCFERRAN, PH.D.
ERIN E. WAGNER, PH.D.
SHARI F. HASAN, PH.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, PH.D.
CRISTINE HOWLEY, PH.D.

* Admitted in NY only
** Admitted in TX only

February 22, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/879,312
Title: *Human c-Maf Compositions and Methods of Use Therefor*
Inventors: Laurie H. Glimeher and John Douhan III
Filed: June 12, 2001
Attorney's Docket No.: HUI-027CPDV1

Dear Sir:

I enclose herewith for filing in the above-identified patent application the following.

1. Information Disclosure Statement (2 pages);
2. Form PTO-449 (1 page); and
3. Pre-Paid Acknowledgment Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:

February 22, 2002

/ Date

2/22/02

Cynthia L. Kanik, Ph.D., Reg. No. 37,320

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Cynthia L. Kanik, Ph.D.
Reg. No. 37,320
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Laurie H. Glimcher and
John Douhan III

Serial No.: 09/879,312

Filed: June 12, 2001

For: *Human c-Maf Compositions and Methods of Use
Therefor*

Attorney Docket No.: HUI-027CPDV1

Group Art Unit: 1632

Examiner:

Commissioner for Patents
Washington, D.C. 20231

REC RECEIVED
MAY 6 2002
TECH CEN/MAK
TECH CENTER 1600/2900

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

February 22, 2002
Date of Signature and of Mail Deposit

Cynthia L. Kanik, Ph.D.
Registration No. 37,320
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Divisional Application of U.S. Serial No. 09/086,010, filed May 27, 1998 (Atty. Docket No. HUI-027CP), which is a Continuation-in-Part Application of U.S. Serial No. 09/030,579, filed February 24, 1998 (Atty. Docket No. HUI-027). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance

with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Cynthia L. Kanik, Ph.D.
Registration No. 37,320
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400
Date: February 22, 2002

GAD/CLK/RKN/alf

APPLICANT FACSIMILE OF FORM PTO-1444 REV. 8/80	U.S. GOVERNMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY/DOCKET NO HUI-027CPDV1	SERIAL NO 09/879,312
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Laurie H. Glimcher and John Douhan III	GROUP
		FILED DATE June 12, 2001	1632

MAR 08 2002

U S PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	NAME	CLAIMS	DETAILED	FILED DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COPY	CLASS	SUBCLASS	TRANSLATION YES NO
A1	WO 97/39721	10/97	PCT			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A1	Andrews, N.C. et al. "The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the <i>v-maf</i> oncogene," <i>PNAS., USA</i> , 90 (1993)
A3	Blank et al. "Human MafG is a functional partner for p45 NF-E2 in activating globin gene expression," <i>Blood</i> 89(11) 3925-35
A4	Chesi, Marta et al. (1998) "Frequent Dysregulation Of The c-maf Proto-Oncogene at 16q23 By Translocation to An Ig Locus In Multiple Myeloma" <i>Blood</i> . 91(12):4457-4463
A5	Ebert et al. "A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig," <i>Mol. Endocrinol.</i> 2(3):277-83 (1988)
A6	Fujiwara, K.T. et al. "Two new members of the <i>maf</i> oncogene family, <i>mafK</i> and <i>maff</i> , encode nuclear b-Zip proteins lacking putative trans-activator domain," <i>Oncogene</i> , 8:2371-2380 (1993)
A7	Hammer et al. "Genetic engineering of mammalian embryos," <i>J. Animal Sci.</i> 63(1):269-78 (1986)
A8	Ho, I-Cheng et al (1996) "The Proto-Oncogene c-maf IS Responsible For Tissue-Specific Expression Of Interleukin-4", <i>Cell</i> , 85(7):973-983
A9	Igarashi, K. et al. "Activity and Expression of Murine Small Maf Family Protein MafK," <i>The Journal of Biological Chemistry</i> , 270(13):7615-7624 (March 31, 1995)
A10	Kataoka, K. et al. "Small Maf Proteins Heterodimerize with Fos and May Act as Competitive Repressors of the NF-E2 Transcription Factor," <i>Mol. Cell. Biol.</i> , 15:2180-90 (1995)
A11	Kataoka, K. et al. "Structure-Function Analysis of the <i>maf</i> Oncogene Product, a Member of the b-zip Protein Family," <i>Journal of Virology</i> , 67(4):2133-2141 (April 1993)
A12	Kataoka, K et al. GenBank™ Accession Number D28596 for Chicken gene for c-maf proto-oncogene product c-Maf, short form complete cds and long form 1 st exon.
A13	Kurchner, C. et al. GenBank™ Accession Number S74567 for c-maf=c-Maf protein (proto-oncogene) [mice, BALB/c, cerebellum, mRNA, 2736 nt]
A14	Kurschner, C. et al. "The <i>maf</i> Proto-oncogene Stimulates Transcription from Multiple Sites in a Promoter That Directs Purkinje Neuron-Specific Gene Expression," <i>Mol Cell Biol</i> , 15 246-54 (1995)
A15	Mullins et al. "Transgenesis in the rat and larger mammals," <i>J. Clin. Invest.</i> 97(7):1557-60 (1996)
A16	Swaroop, A. et al. "A conserved retina-specific gene encodes a basic motif/leucine zipper domain", <i>Proc. Natl. Acad. Sci. USA</i> , 89:266-270 (January 1992)
A17	Toki et al. "Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif," <i>Oncogene</i> 14:1901-10
A18	Wall et al. "Transgenic dairy cattle: genetic engineering on a large scale," <i>J. Dairy Sci.</i> 80(9):2213-24 (1996)

Examiner

Date Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 12 2002

TECH CENTER 1600-290